Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents

We previously demonstrated the efficacy of the COVID-19 vaccine candidate, SCB-2019, in adults in the SPECTRA phase 2/3 efficacy study. We extended the study to include 1278 healthy 12–17-year-old adolescents in Belgium, Colombia, and the Philippines who received either two doses of SCB-2019 or plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Pio, Bravo, Lulu, Buntinx, Erik, Borja-Tabora, Charissa, Velasquez, Hector, Rodriquez, Edith Johana, Rodriguez, Camilo A., Carlos, Josefina, Montellano, May Emmeline B., Alberto, Edison R., Salvani-Bautista, Milagros, Huang, Yung, Hu, Branda, Li, Ping, Han, Htay Htay, Baccarini, Carmen, Smolenov, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronavirus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294745/
https://www.ncbi.nlm.nih.gov/pubmed/37226504
http://dx.doi.org/10.1080/21645515.2023.2206359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294745/
https://www.ncbi.nlm.nih.gov/pubmed/37226504
http://dx.doi.org/10.1080/21645515.2023.2206359

Ejemplares similares